A Study to Assess the Safety, Tolerability and PK Profile of FDL176 in Healthy and CF Participants
Status:
Completed
Trial end date:
2018-05-31
Target enrollment:
Participant gender:
Summary
This is a 5-part study of FDL176. Part 1 is a double blind, placebo-controlled, dose
escalation study in healthy male participants. Part 2 is a single dose, open-label study in
healthy male participants. Part 3 is a single dose, double blind, placebo-controlled study in
healthy female participants. Part 4 is a randomised, double-blind, placebo-controlled,
dose-escalation study in healthy male and female participants.Part 5 is a single dose,
open-label study in male and female participants with CF.